What it's for (Indications)
- Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is typically prescribed when metformin, sulfonylureas, or thiazolidinediones alone or in combination do not provide adequate glycemic control.
- This medication can be utilized as monotherapy or in conjunction with other oral antidiabetic agents, such as metformin, sulfonylureas, thiazolidinediones, or a combination of these, and also with basal insulin.
- Its role is to help patients achieve target hemoglobin A1c levels by managing postprandial and fasting glucose concentrations effectively.
- The clinical trials supporting its approval have demonstrated its efficacy in reducing HbA1c and fasting plasma glucose, often accompanied by modest weight loss, making it a valuable option in comprehensive diabetes management strategies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The initial dosage of exenatide (Byetta) is 5 mcg administered subcutaneously twice daily. Doses should be injected within 60 minutes prior to the morning and evening meals. It is crucial not to administer the medication after a meal. After one month of treatment, if additional glycemic control is required and the 5 mcg dose has been well-tolerated, the dosage may be increased to 10 mcg twice daily. Injections should be administered in the thigh, abdomen, or upper arm. Patients should be advised that if a dose is missed, they should skip that dose and resume their next scheduled dose as prescribed, without attempting to take an extra dose or increase the next dose to compensate. Proper injection technique and site rotation are essential for optimal absorption and to minimize local reactions. |
Safety & Warnings
Common Side Effects
- Common side effects associated with exenatide include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and dyspepsia.
- Nausea is particularly prevalent at the start of therapy but often diminishes over time with continued use.
- Other frequently reported side effects include headache and injection site reactions like redness or itching.
- A significant concern is hypoglycemia, especially when exenatide is co-administered with a sulfonylurea or insulin, necessitating careful dose adjustments of these concomitant medications.
- More serious, albeit less common, side effects include acute pancreatitis, which can be severe and life-threatening; acute renal failure or worsening of chronic renal failure; and severe hypersensitivity reactions, including anaphylaxis and angioedema.
- Gallbladder disorders, such as cholelithiasis and cholecystitis, have also been reported.
- Patients must be educated about the symptoms of these serious conditions.
Serious Warnings
- Black Box Warning: While exenatide (Byetta, the immediate-release formulation) does not carry an FDA Black Box Warning for thyroid C-cell tumors, unlike its extended-release counterpart, exenatide is associated with several serious safety concerns that warrant explicit mention and careful consideration, akin to a 'Serious Warnings' section. **Serious Warnings:** **1. Acute Pancreatitis Risk:** Exenatide has been associated with cases of acute pancreatitis, including severe and fatal forms, such as hemorrhagic or necrotizing pancreatitis. Patients must be educated about the symptoms of acute pancreatitis, which typically include persistent, severe abdominal pain that may radiate to the back, and may or may not be accompanied by vomiting. If pancreatitis is suspected, exenatide should be promptly and permanently discontinued, and appropriate medical management initiated. Re-initiation of exenatide is not recommended after an episode of pancreatitis. **2. Renal Impairment and Acute Kidney Injury:** Postmarketing reports have described cases of altered renal function, including increased serum creatinine, renal impairment, worsening of chronic renal failure, and acute renal failure, some requiring hemodialysis, in patients treated with exenatide. These events often occurred in patients with underlying renal disease or other risk factors for renal impairment. Caution is advised when initiating or escalating exenatide in patients with pre-existing renal impairment, and it is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease. Monitoring of renal function is crucial, especially in vulnerable patients.
- Exenatide carries several important warnings.
- A primary concern is the risk of acute pancreatitis; patients should be monitored for characteristic symptoms such as persistent, severe abdominal pain that may radiate to the back, possibly accompanied by vomiting.
- If pancreatitis is suspected, exenatide must be discontinued immediately.
- Furthermore, postmarketing reports indicate altered renal function, including acute renal failure, in patients treated with exenatide, particularly those with pre-existing renal disease or risk factors.
- Exenatide is not recommended for individuals with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease.
- The risk of hypoglycemia is increased when exenatide is used in combination with a sulfonylurea or insulin, requiring potential dose reduction of these agents.
- Exenatide slows gastric emptying, and it has not been studied in patients with severe gastrointestinal disease, including gastroparesis, hence its use is not recommended in such patients.
- Serious hypersensitivity reactions have been reported, necessitating immediate discontinuation if suspected.
- Additionally, patients may develop anti-exenatide antibodies, which could potentially lead to reduced glycemic control.
How it Works (Mechanism of Action)
Exenatide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the actions of the natural incretin hormone GLP-1. Its primary mechanism involves enhancing glucose-dependent insulin secretion from the pancreatic beta-cells, meaning it stimulates insulin release only when blood glucose levels are elevated, thereby minimizing the risk of hypoglycemia in normoglycemic states. Concurrently, exenatide suppresses inappropriately high glucagon secretion from pancreatic alpha-cells, both postprandially and during fasting, which contributes to a reduction in hepatic glucose output. Another crucial effect is the slowing of gastric emptying, which helps to attenuate postprandial glucose excursions by delaying nutrient absorption. Furthermore, exenatide may promote satiety through central nervous system mechanisms, potentially leading to reduced caloric intake and modest weight loss. These multifaceted actions contribute to improved glycemic control in individuals with type 2 diabetes mellitus.
Commercial Brands (Alternatives)
No other brands found for this formula.